Effects of Prazosin on the Attention-Enhancing Effects of Nicotine

The Effects of Prazosin on the Attention-Enhancing Effects of Nicotine in Healthy Non-Smokers

To test whether specific aspects of the attention-enhancing effects of nicotine may be mediated by down-stream activation of alpha1 adrenoceptors, the interaction of nicotine and the alpha1 adrenergic antagonist prazosin on cognitive task performance will be tested in human non-smokers. The effects of a low-dose nicotine patch vs. a placebo patch will be tested in the presence and absence of prazosin over 4 test sessions.

Study Overview

• Status: Withdrawn
• Conditions: no Condition, Basic Science
• Intervention / Treatment: Drug: Placebo; Drug: Nicotine; Drug: Prazosin; Drug: Nicotine + Prazosin

Detailed Description

Drugs that activate nicotinic acetylcholine receptors (nAChRs), such as nicotine, have cognitive enhancing, and in particular attention-enhancing effects that may be of clinical benefit to individuals with cognitive deficits, such as those diagnosed with Alzheimer's disease, schizophrenia, or ADHD. nAChR agonists can increase the release of other neurotransmitters in the brain, including dopamine, noradrenaline, serotonin, glutamate and GABA. To date, it is unknown which of these actions is central to mediating the attention-enhancing effects of nAChR agonists. Such knowledge would channel drug development efforts onto subtypes of the nAChR expressed on and activating the target system, but not systems such as the subcortical dopamine system involved in unwanted effects of nAChR agonists (e.g., dependence).

Preclinical studies have suggested that the noradrenergic system is critical to the attention-enhancing effects of the prototypical nAChR agonist nicotine. Activation of alpha1-adrenergic receptors appears to be involved in broadening the attentional window, an effect shared with nicotine. The aim of the present study is to test whether the effects of nicotine on broad monitoring may be mediated by alpha1 adrenoceptors by testing the interaction of nicotine and the predominantly alpha1 adrenergic antagonist prazosin in healthy human non-smokers. The effects of a low-dose nicotine patch vs. a placebo patch will be tested in the presence and absence of prazosin in a 2 x 2 within-subject design, over 4 repeated test sessions, in healthy never-smokers. Each participant is asked to complete for test session, on separate days. In each session, a skin patch will be applied and a capsule given by mouth. In one session, both are a placebo. In another session, the patch contains nicotine (7 mg/24 hrs) and the capsule is a placebo. In another session, the patch is a placebo and the capsule contains 1 mg of prazosin. In another session, the patch contains nicotine and the capsule contains prazosin. The sequence of these testing conditions is counterbalanced and double-blind.

• Study Type: Interventional
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Aged 21 to 55 years.
• Smoked no more that 40 cigarettes, cigars or cigarillos in lifetime.
• Smoked no cigarettes, cigars or cigarillos in the last year.
• No exposure to any nicotine-containing product in the last month.
• Normal or corrected to normal vision (at least 20/80).

Exclusion Criteria:

• Pregnant or breast-feeding.
• Drug or alcohol abuse or dependence currently or in the last 2 years.
• DSM Axis I mood, anxiety or psychotic disorder.
• Cardiovascular or cerebrovascular disease.
• Hypertension (resting systolic BP above 150 or diastolic above 95 mm Hg).
• Hypotension (resting systolic BP below 90 or diastolic below 60).
• Bradycardia (heart rate <60 bpm).
• Impaired liver or kidney function.
• Severe asthma.
• Obstructive pulmonary disease.
• Type I diabetes.
• Use of any centrally active medications.
• Use of any cardiovascular drugs, including blood pressure medications and antiarrhythmics.
• Use of diuretic medication.
• History of or current neurological illnesses, such as stroke, seizure disorders, neurodegenerative diseases, or organic brain syndrome.
• Learning disability, mental retardation, or any other condition that impedes cognition.
• Planned eye surgery.
• Inability to perform the Rapid Visual Information Processing Task.
• Known hypersensitivity to prazosin, any quinazolines, or nicotine.
• Narcolepsy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Nicotine-Prazosin Interaction Study; Over four test days, each participant will be tested with placebo, nicotine alone, prazosin alone, and nicotine + prazosin, in a double-blind sequence.	Drug: Placebo; placebo skin patch + placebo capsule; Drug: Nicotine; nicotine patch (7 mg/24 hrs) + placebo capsule; Drug: Prazosin; placebo patch (7 mg/24 hrs) + prazosin capsule (1 mg); Drug: Nicotine + Prazosin; nicotine patch (7 mg/24 hrs) + prazosin capsule (1 mg)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Spatial Attentional Resource Allocation Task reaction time	average reaction time of trials with a signal detection response	5 hrs after patch application (=2.5 hr after ingestion of capsule)
Spatial Attentional Resource Allocation Task omission errors	percentage of trials on which no response was registered	5 hrs after patch application (=2.5 hr after ingestion of capsule)
Rapid Visual Information Processing Task hit rate	percentage of targets detected	5 hrs after patch application (=2.5 hr after ingestion of capsule)
Rapid Visual Information Processing Task reaction time	average reaction time on trials with a correct response	5 hrs after patch application (=2.5 hr after ingestion of capsule)
Change Detection Task accuracy	percentage of correct responses	5 hrs after patch application (=2.5 hr after ingestion of capsule)
Change Detection reaction time	average reaction time across trials	5 hrs after patch application (=2.5 hr after ingestion of capsule)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Vital signs: heart rate	beats per minute	hourly for 8 hours on each test day
Blood pressure	mmHg	hourly for 8 hours on each test day

Collaborators and Investigators

• Sponsor: University of Maryland, Baltimore

Study record dates

Study Major Dates

• Study Start (Anticipated): March 1, 2018
• Primary Completion (Anticipated): January 1, 2019
• Study Completion (Anticipated): January 1, 2019

Study Registration Dates

• First Submitted: January 24, 2018
• First Submitted That Met QC Criteria: January 24, 2018
• First Posted (Actual): January 31, 2018

Study Record Updates

• Last Update Posted (Actual): August 19, 2019
• Last Update Submitted That Met QC Criteria: August 15, 2019
• Last Verified: August 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Adrenergic Antagonists; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Antihypertensive Agents; Autonomic Agents; Peripheral Nervous System Agents; Cholinergic Agents; Ganglionic Stimulants; Nicotinic Agonists; Cholinergic Agonists; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Nicotine; Prazosin
• Other Study ID Numbers: HP-00078832

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No